
Takafumi Mie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6013937/publications.pdf Version: 2024-02-01



Τλκλειιμι Μιε

#	Article	IF	CITATIONS
1	Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. BMC Cancer, 2020, 20, 449.	1.1	39
2	The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. International Journal of Clinical Oncology, 2021, 26, 1293-1303.	1.0	25
3	A novel laserâ€cut fully covered metal stent with antiâ€reflux valve in patients with malignant distal biliary obstruction refractory to conventional covered metal stent. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 563-571.	1.4	21
4	Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study. Annals of Surgical Oncology, 2022, 29, 5038-5050.	0.7	16
5	Improved prognosis of pancreatic cancer patients with peritoneal metastasis. Pancreatology, 2021, 21, 903-911.	0.5	15
6	Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. International Journal of Molecular Sciences, 2022, 23, 1205.	1.8	13
7	Early-onset pancreatic cancer: Clinical characteristics and survival outcomes. Pancreatology, 2022, 22, 507-515.	0.5	12
8	Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. International Journal of Clinical Oncology, 2021, 26, 543-551.	1.0	11
9	Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. Japanese Journal of Clinical Oncology, 2021, 51, 1416-1422.	0.6	11
10	Comprehensive comparison of clinicopathological characteristics, treatment, and prognosis of borderline resectable pancreatic cancer according to tumor location. Pancreatology, 2020, 20, 1123-1130.	0.5	10
11	Novel risk factors for recurrent biliary obstruction and pancreatitis after metallic stent placement in pancreatic cancer. Endoscopy International Open, 2020, 08, E1603-E1610.	0.9	10
12	The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer. Japanese Journal of Clinical Oncology, 2021, 51, 604-611.	0.6	10
13	Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer. Pancreas, 2021, 50, 595-601.	0.5	7
14	Pancreatic follicular lymphoma: a report of two cases and literature review. Clinical Journal of Gastroenterology, 2021, 14, 1756-1765.	0.4	7
15	Ki-67 Labeling Index Variability Between Surgically Resected Primary and Metastatic Hepatic Lesions of Gastroenteropancreatic Neuroendocrine Neoplasms. International Journal of Surgical Pathology, 2021, 29, 106689692199071.	0.4	6
16	The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer. Japanese Journal of Clinical Oncology, 2021, 51, 728-736.	0.6	5
17	The safety and efficacy of self-expandable metallic stent placement for malignant biliary obstruction with surgically altered anatomy. Scandinavian Journal of Gastroenterology, 2021, 56, 94-102.	0.6	4
18	A case of percutaneous transhepatic portal vein stent placement and endoscopic injection sclerotherapy for duodenal variceal rupture occurring during chemotherapy for unresectable perihilar cholangiocarcinoma. Clinical Journal of Gastroenterology, 2020, 13, 1150-1156.	0.4	3

Такағимі Міе

#	Article	IF	CITATIONS
19	Comparison of Endoscopic Ultrasound-Guided Tissue Acquisition Using a 20-Gauge Menghini Needle with a Lateral Forward Bevel and a 22-Gauge Franseen Needle: A Single-Center Large Cohort Study. Clinical Endoscopy, 2021, 54, 730-738.	0.6	3
20	Longâ€term outcomes of endoscopic double stenting using an antiâ€reflux metal stent for combined malignant biliary and duodenal obstruction. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, , .	1.4	3
21	A case of endoscopic ultrasound-guided hepaticogastrostomy for obstructive jaundice caused by intraductal papillary mucinous neoplasm-associated pancreatobiliary fistula. Clinical Journal of Gastroenterology, 2021, 14, 893-898.	0.4	2
22	A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma. Clinical Journal of Gastroenterology, 2021, 14, 1571-1577.	0.4	2
23	Comparison of clinicopathological characteristics and prognosis of borderline resectable pancreatic cancer according to the location of the primary tumor Journal of Clinical Oncology, 2020, 38, 662-662.	0.8	2
24	Diagnostic yield of endoscopic ultrasound-guided tissue acquisition for small solid pancreatic lesions. Endoscopy International Open, 2020, 08, C2-C2.	0.9	2
25	Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer. Internal Medicine, 2022, 61, 2741-2746.	0.3	2
26	Observation of mucinous cystic neoplasms (MCN):. Suizo, 2020, 35, 201-212.	0.1	1
27	Impact of Histological Features on Adjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Carcinoma. Anticancer Research, 2022, 42, 2645-2655.	0.5	1
28	Percutaneous insertion of a jejunal tube via the collapsed blind end of elevated jejunum by a balloon puncturing method assisted by a balloon enteroscope. Journal of Hepato-Biliary-Pancreatic Sciences, 2020, 27, 663-664.	1.4	0
29	Two case reports of brain metastases in patients with pancreatobiliary neuroendocrine carcinoma. Clinical Journal of Gastroenterology, 2021, 14, 386-390.	0.4	0
30	Blind Spot of Enteral Stenting for Malignant Duodenal Obstruction due to Colon Cancer: A Rare Case of Duodenocolonic Fistula. Clinical Endoscopy, 2021, 54, 443-444.	0.6	0
31	ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?. Annals of Surgical Oncology, 2022, , 1.	0.7	0
32	ASO Visual Abstract: Optimizing the Indications for Conversion Surgery Based on an Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study. Annals of Surgical Oncology, 2022, , 1.	0.7	0